BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1385 related articles for article (PubMed ID: 9394030)

  • 1. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
    Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
    Johnson KA; Prakash C
    Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C; Cui D; Potchoiba MJ; Butler T
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
    Ehlhardt WJ; Woodland JM; Baughman TM; Vandenbranden M; Wrighton SA; Kroin JS; Norman BH; Maple SR
    Drug Metab Dispos; 1998 Jan; 26(1):42-51. PubMed ID: 9443851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
    Prakash C; Kamel A; Anderson W; Howard H
    Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys.
    Chang M; Sood VK; Kloosterman DA; Hauer MJ; Fagerness PE; Sanders PE; Vrbanac JJ
    Drug Metab Dispos; 1997 Jul; 25(7):814-27. PubMed ID: 9224776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
    Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
    Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats.
    Lee J; Yoo HH; Rhim KJ; Sohn DR; Kim DH
    Rapid Commun Mass Spectrom; 2007; 21(7):1139-49. PubMed ID: 17318927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
    Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
    Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion and metabolism of trovafloxacin in humans.
    Dalvie DK; Khosla N; Vincent J
    Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.